The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity (Q44210730)

30 November 2017

The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity (English)

1 reference

30 November 2017

0 references

1 reference

Marcelo Rizzatti Luizon

2

1 reference

30 November 2017

V A Belo

1

1 reference

30 November 2017

R Lacchini

3

1 reference

30 November 2017

J A Miranda

4

1 reference

30 November 2017

C M M Lanna

5

1 reference

30 November 2017

D C Souza-Costa

6

1 reference

30 November 2017

J E Tanus-Santos

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

12 September 2013

1 reference

International Journal of Obesity

30 November 2017

1 reference

30 November 2017

39

1 reference

30 November 2017

1

1 reference

30 November 2017

130-135

1 reference

https://scigraph.springernature.com/pub.10.1038/ijo.2013.173

30 November 2017

0 references

cites work

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin, glucose metabolism and vascular disease: a review of evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Vascular endothelial growth factor haplotypes associated with childhood obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Plasma visfatin concentrations and fat depot-specific mRNA expression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin in juvenile obesity - the effect of obesity intervention and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

The release of the adipocytokine visfatin is regulated by glucose and insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Serum visfatin levels, adiposity and glucose metabolism in obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Definition and clinical importance of haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Common variants of IL6, LEPR, and PBEF1 are associated with obesity in Indian children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Obesity and the metabolic syndrome in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

A New Statistical Method for Haplotype Reconstruction from Population Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJO.2013.173

Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Con

21 January 2018

1 reference

12 December 2020

The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance

1 reference

12 December 2020

Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis

1 reference

12 December 2020

Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.

1 reference

12 December 2020

Adipose tissue as an endocrine organ

1 reference

12 December 2020

A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease

1 reference

12 December 2020

CDC growth charts: United States

1 reference

12 December 2020

Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis

1 reference

12 December 2020

Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans

1 reference

12 December 2020

Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children

1 reference

12 December 2020

Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension

1 reference

12 December 2020

The adipokine visfatin is markedly elevated in obese children

1 reference

12 December 2020

Serum visfatin increases with progressive beta-cell deterioration

1 reference

12 December 2020

Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices

1 reference

12 December 2020

Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity

1 reference

12 December 2020

Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin

1 reference

12 December 2020

Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children

1 reference

12 December 2020

Identifiers

DOI

10.1038/IJO.2013.173

1 reference

30 November 2017

1 reference